BSTG   $4.01  0.25% Market Closed

Biostage Inc
Last Events:

2023-07-20 Signal in RSI changed from bearish recovery to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.

2023-07-20 Trend Power changed from strong to medium strength.

2023-07-19 Signal in Stochastic changed from bearish reversal to bearish. The stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: down-crossing the middle level.

2023-07-18 Trend pattern changed from восходящий треугольник to расходящийся клин с наклоном вниз.

2023-07-18 Signal in Stochastic changed from bearish recovery to bearish reversal. The stochastic indicator is in the upper part of the neutral territory and left the overbought territory. These factors indicate that perhaps the upside trend is coming to an end price will probably head south Last signal: main and signal line crossing.

2023-07-18 Signal in MACD changed from bearish recovery to bullish reversal. Oscillator MACD is in the negative territory it's higher than the signal line and grows. These factors mean that the falling period is over. Last signal: main and signal line crossing.

2023-07-18 Signal in RSI changed from bearish to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.

2023-07-18 Trend changed from up and flat to turning down.


Current temperature: 0.74
ST: 0, Cor:

Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Buy Buy -
rsi ActivelyBuy ActivelyBuy -
macd - - -
stoch - - -
ma20 ActivelyBuy ActivelyBuy -
ma50 - - -
ma100 - Buy -
Candlestick PatternJuly 12, 2023 Three Stars -
ISIN US09074M2026
ceo Mr. Junli He
Website https://biostage.com
Biostage, Inc., a biotechnology company, offers products to cure patients of cancers, injuries, and birth defects of the gastro-intestinal tract and the airways. The company's pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs, as well as product candidates to treat cancer, injury, and birth defects of the bronchus. Its lead product candidate is Biostage Esophageal Implant for the treatment of severe esophageal disease. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2009 and is headquartered in Holliston, Massachusetts.